1-11 of 11
Alexandra Leary
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy

Elisa Yaniz-Galende, Qinghe Zeng, Juan F. Bejar-Grau, Christophe Klein, Felix Blanc-Durand, Audrey Le Formal, Eric Pujade-Lauraine, Laure Chardin, Elodie Edmond, Virginie Marty, Isabelle Ray-Coquard, Florence Joly, Gwenael Ferron, Patricia Pautier, Dominique Berton-Rigaud, Alain Lortholary, Nadine Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamaichhane, Diana Bello Roufai, Justine Gantzer, Etienne Rouleau, Catherine Genestie, Alexandra Leary
Journal: Clinical Cancer Research
Clin Cancer Res (2024) 30 (13): 2790–2800.
https://doi.org/10.1158/1078-0432.CCR-23-3836
Published: 01 July 2024
View article titled, Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy
Open the PDF for Spatial Profiling of Ovarian Carcinoma and Tumor Microenvironment Evolution under Neoadjuvant Chemotherapy in another window
Includes: Supplementary data
Journal Articles

Clinical Relevance of BRCA1 Promoter Methylation Testing in Patients with Ovarian Cancer

Félix Blanc-Durand, Roseline Tang, Margaux Pommier, Marzieh Nashvi, Sophie Cotteret, Catherine Genestie, Audrey Le Formal, Patricia Pautier, Judith Michels, Maria Kfoury, Robert Hervé, Sylvie Mengue, Estelle Wafo, Antoine Elies, Gregoire Miailhe, Jennifer Uzan, Etienne Rouleau, Alexandra Leary
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (16): 3124–3129.
https://doi.org/10.1158/1078-0432.CCR-22-3328
Published: 15 August 2023
View article titled, Clinical Relevance of <em>BRCA1</em> Promoter Methylation Testing in Patients with Ovarian Cancer
Open the PDF for Clinical Relevance of <em>BRCA1</em> Promoter Methylation Testing in Patients with Ovarian Cancer in another window
Includes: Supplementary data
Journal Articles

Therapy-related Myeloid Neoplasms Following PARP Inhibitors—Response

Vincent Marmouset, Pierre-Marie Morice, Arnaud Pagès, Alexandra Leary, Jean-Baptiste Micol
Journal: Clinical Cancer Research
Clin Cancer Res (2023) 29 (6): 1158–1159.
https://doi.org/10.1158/1078-0432.CCR-23-0164
Published: 14 March 2023
View article titled, Therapy-related Myeloid Neoplasms Following PARP Inhibitors—Response
Open the PDF for Therapy-related Myeloid Neoplasms Following PARP Inhibitors—Response in another window
Journal Articles

Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience

Vincent Marmouset, Justine Decroocq, Sylvain Garciaz, Gabriel Etienne, Amine Belhabri, Sarah Bertoli, Lauris Gastaud, Célestine Simand, Sylvain Chantepie, Madalina Uzunov, Alexis Genthon, Céline Berthon, Edmond Chiche, Pierre-Yves Dumas, Jacques Vargaftig, Géraldine Salmeron, Emilie Lemasle, Emmanuelle Tavernier, Jérémy Delage, Marion Loirat, Nadine Morineau, Félix Blanc-Durand, Patricia Pautier, Véronique Vergé, Nathalie Auger, Myrtille Thomas, Laetitia Stefani, Marion Lepelley, Thomas Boyer, Sylvain Thepot, Marie-Pierre Gourin, Pascal Bourquard, Matthieu Duchmann, Pierre-Marie Morice, Mauricette Michallet, Lionel Adès, Pierre Fenaux, Christian Récher, Hervé Dombret, Arnaud Pagès, Christophe Marzac, Alexandra Leary, Jean-Baptiste Micol, on behalf of UNIHEM, French Network of Pharmacovigilance Centers, ALFA, FILO, and GFM
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (23): 5211–5220.
https://doi.org/10.1158/1078-0432.CCR-22-1622
Published: 01 December 2022
View article titled, Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience
Open the PDF for Therapy-related Myeloid Neoplasms Following PARP Inhibitors: Real-life Experience in another window
Includes: Supplementary data
Journal Articles

CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial

Benoit You, Patrick Robelin, Michel Tod, Christophe Louvet, Jean-Pierre Lotz, Sophie Abadie-Lacourtoisie, Michel Fabbro, Christophe Desauw, Nathalie Bonichon-Lamichhane, Jean-Emmanuel Kurtz, Philippe Follana, Marianne Leheurteur, Francesco Del Piano, Gwénael Ferron, Gaëtan De Rauglaudre, Isabelle Ray-Coquard, Pierre Combe, Annick Chevalier-Place, Florence Joly, Alexandra Leary, Eric Pujade-Lauraine, Gilles Freyer, Olivier Colomban
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (17): 4625–4632.
https://doi.org/10.1158/1078-0432.CCR-20-0054
Published: 01 September 2020
View article titled, CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial
Open the PDF for CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial in another window
Includes: Supplementary data
Journal Articles

Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study

Olivier Colomban, Michel Tod, Alexandra Leary, Isabelle Ray-Coquard, Alain Lortholary, Anne Claire Hardy-Bessard, Jacobus Pfisterer, Andreas Du Bois, Christian Kurzeder, Alexander Burges, Julien Péron, Gilles Freyer, Benoit You
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (17): 5342–5350.
https://doi.org/10.1158/1078-0432.CCR-18-3335
Published: 03 September 2019
View article titled, Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study
Open the PDF for Early Modeled Longitudinal CA-125 Kinetics and Survival of Ovarian Cancer Patients: A GINECO AGO MRC CTU Study in another window
Includes: Supplementary data
Journal Articles

Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas

Marthe M. de Jonge, Aurélie Auguste, Lise M. van Wijk, Philip C. Schouten, Matty Meijers, Natalja T. ter Haar, Vincent T.H.B.M. Smit, Remi A. Nout, Mark A. Glaire, David N. Church, Harry Vrieling, Bastien Job, Yannick Boursin, Cor D. de Kroon, Etienne Rouleau, Alexandra Leary, Maaike P.G. Vreeswijk, Tjalling Bosse
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2019) 25 (3): 1087–1097.
https://doi.org/10.1158/1078-0432.CCR-18-1443
Published: 01 February 2019
View article titled, Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
Open the PDF for Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas in another window
Includes: Supplementary data
Journal Articles

Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)

Robert L. Coleman, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, David M. O’Malley, Terri Cameron, Lara Maloney, Sandra Goble, Kevin Lin, James Sun, Heidi Giordano, Jonathan A. Ledermann
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15_Supplement): PR06.
https://doi.org/10.1158/1557-3265.OVCA17-PR06
Published: 01 August 2018
View article titled, Abstract PR06: ARIEL3: A phase 3, randomized, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian cancer (OC)
Journal Articles

Abstract AP28: BRCA1 and RAD51C Promoter Hypermethylation Confer Sensitivity to PARP Inhibitors in Patients with Platinum Sensitive Ovarian Carcinoma

Elizabeth Swisher, Maria Harrell, Kevin K. Lin, Clare Scott, Sandra Goble, Amit Oza, Robert L. Coleman, Gottfried Konecny, Anna V. Tinker, David M. O'Malley, Rebecca Kristeleit, Ling Ma, James Brenton, Katherine Bell-McGuinn, Ana Oaknin, Alexandra Leary, Elaina Mann, Heidi Giordano, Mitch Rapon, Iain McNeish, Scott H. Kaufmann
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (11_Supplement): AP28.
https://doi.org/10.1158/1557-3265.OVCASYMP16-AP28
Published: 31 May 2017
View article titled, Abstract AP28: <em>BRCA1</em> and <em>RAD51C</em> Promoter Hypermethylation Confer Sensitivity to PARP Inhibitors in Patients with Platinum Sensitive Ovarian Carcinoma
Journal Articles

Abstract A11: NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib.

Iain A. McNeish, Kevin K. Lin, James X. Sun, Sandra Goble, Amit Oza, Robert L. Coleman, Clare L. Scott, Gottfried Konecny, Anna V. Tinker, David M. O'Malley, Rebecca Kristeleit, Ling Ma, James D. Brenton, Katherine Bell-McGuinn, Ana Oaknin, Alexandra Leary, Elaina Mann, Heidi Giordano, Roman Yelensky, Mitch Raponi, Elizabeth Swisher
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (2_Supplement): A11.
https://doi.org/10.1158/1557-3265.OVCA15-A11
Published: 15 January 2016
View article titled, Abstract A11: NGS-based tumor genomic profiling to identify ovarian cancer patients who benefit from the PARP inhibitor rucaparib.
Journal Articles

Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)

Alexandra Leary, Abigail Evans, Stephen R.D. Johnston, Roger A'Hern, Judith M. Bliss, Rashmita Sahoo, Simone Detre, Benjamin P. Haynes, Margaret Hills, Catherine Harper-Wynne, Nigel Bundred, Gill Coombes, Ian Smith, Mitch Dowsett
Journal: Clinical Cancer Research
Series: Author Choice
Clin Cancer Res (2015) 21 (13): 2932–2940.
https://doi.org/10.1158/1078-0432.CCR-14-1428
Published: 30 June 2015
View article titled, Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039)
Open the PDF for Antiproliferative Effect of Lapatinib in HER2-Positive and HER2-Negative/HER3-High Breast Cancer: Results of the Presurgical Randomized MAPLE Trial (CRUK E/06/039) in another window
Includes: Supplementary data